TL;DR: Aetna, a CVS Health company, modified CPB 0926 covering transperineal peri-prostatic placement of biodegradable material (Barrigel, SpaceOAR) for prostate cancer, with an effective date of January 5, 2026. The covered procedure bills under CPT 55874. Here's what billing teams need to know.
This Aetna transperineal biodegradable spacer coverage policy draws a clear line: CPT 55874 is covered when used to reduce rectal toxicity during prostate radiotherapy, and it's experimental for everything else. The policy sits under CPB 0926 Aetna system and applies to radiation oncology, urology, and any practice billing the procedure in conjunction with prostate cancer treatment codes like ICD-10 C61.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Transperineal Placement of Biodegradable Material for Prostate Cancer |
| Policy Code | CPB 0926 |
| Change Type | Modified |
| Effective Date | January 5, 2026 |
| Impact Level | Medium |
| Specialties Affected | Radiation Oncology, Urology, Interventional Radiology |
| Key Action | Confirm CPT 55874 claims are linked to prostate radiotherapy intent and paired with ICD-10 C61 before billing |
Aetna Transperineal Biodegradable Spacer Coverage Criteria and Medical Necessity Requirements 2026
Aetna covers transperineal peri-prostatic placement of biodegradable material under one specific condition. The patient must be a man undergoing radiotherapy for prostate cancer, and the procedure's purpose must be reducing rectal toxicity. That's it. That's the entire covered indication.
CPT 55874 is the billing code for this procedure. It covers single or multiple injections performed transperineally to place biodegradable material — brand names include Barrigel and SpaceOAR — in the peri-prostatic space. The spacer creates physical separation between the prostate and rectum during radiation.
Medical necessity under this coverage policy is narrow by design. Aetna is not covering this procedure broadly for prostate cancer patients — only for those whose treatment plan includes radiotherapy and where rectal protection is the documented clinical rationale. Your documentation needs to show both: active or planned prostate radiotherapy and the intent to reduce rectal toxicity.
This policy does not explicitly state prior authorization requirements in the published bulletin, but given the procedure cost and the specificity of the covered indication, treat this like any high-cost oncology service. Verify prior auth requirements through Aetna's portal before scheduling. Missing that step is a fast path to claim denial.
Reimbursement for CPT 55874 is tied directly to the radiotherapy context. Claims submitted without the supporting diagnosis code ICD-10 C61 (malignant neoplasm of prostate) won't have the diagnostic link Aetna needs to confirm medical necessity. Build that pairing into your charge capture now.
Aetna Transperineal Biodegradable Spacer Exclusions and Non-Covered Indications
Aetna's position here is unambiguous. Any use of transperineal peri-prostatic biodegradable material outside of prostate cancer radiotherapy is experimental, investigational, or unproven.
There are no partial exceptions listed. No emerging indications. No coverage with evidence development pathway mentioned. If a provider places Barrigel or SpaceOAR for a reason other than reducing rectal toxicity in a prostate radiotherapy patient, Aetna will not cover it under this policy.
This matters because the clinical community continues to study biodegradable spacers for other potential uses. Any claims filed for off-label or investigational use will face denial under this coverage policy. If your team is billing CPT 55874 in any context beyond the single covered indication, stop and review those claims before the January 5, 2026 effective date.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Transperineal peri-prostatic placement of biodegradable material (Barrigel, SpaceOAR) to reduce rectal toxicity during prostate radiotherapy | Covered | CPT 55874, ICD-10 C61 | Must be in context of radiotherapy; verify prior auth |
| All other indications for transperineal peri-prostatic biodegradable material placement | Experimental / Not Covered | CPT 55874 | Aetna classifies as experimental, investigational, or unproven |
Aetna Transperineal Biodegradable Spacer Billing Guidelines and Action Items 2026
These steps apply to radiation oncology practices, urology groups, and any facility billing CPT 55874 for Aetna-insured patients.
| # | Action Item |
|---|---|
| 1 | Update your charge capture for CPT 55874 before January 5, 2026. Add a hard stop or prompt requiring documentation of the radiotherapy plan and the rectal toxicity reduction rationale. Without both, you're building a denial into the claim from the start. |
| 2 | Pair every CPT 55874 claim with ICD-10 C61. This is the diagnosis code for malignant neoplasm of prostate. It's the only ICD-10 code listed in this policy. Every claim for the covered indication needs this code. |
| 3 | Verify prior authorization requirements before each procedure. This policy bulletin doesn't publish specific prior auth rules, but Aetna commonly requires auth for high-cost procedures tied to cancer treatment. Check Aetna's NaviMedix or provider portal for current auth requirements tied to CPT 55874. |
| 4 | Train your coders on the experimental designation. Any CPT 55874 claim not tied to prostate radiotherapy for rectal toxicity reduction will be denied. Make sure coders and clinicians understand that "prostate cancer" alone is not sufficient — the radiotherapy context is required. |
| 5 | Review any in-flight claims for CPT 55874 now. If you have claims pending or about to be submitted that reference this procedure for off-label indications, pull them before the effective date. Refile only claims that meet the covered criteria. |
| 6 | Cross-check the radiation treatment delivery codes. This policy lists CPT 77401 through 77417 and brachytherapy codes 77767–77772 and 77778 as related codes. These aren't the procedure being covered — they're the radiotherapy codes that establish the treatment context. If you're billing CPT 55874 without a corresponding radiation treatment course documented, expect scrutiny. |
| 7 | If you're unsure how this applies to your payer mix or patient population, talk to your compliance officer before the January 5, 2026 effective date. The covered indication is narrow. A small billing misstep here — filing CPT 55874 outside the covered context — creates both a denial problem and a potential compliance exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Transperineal Biodegradable Spacer Placement Under CPB 0926
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 55874 | CPT | Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s) |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C61 | Malignant neoplasm of prostate |
The Real Issue With This Policy
CPB 0926 is one of the cleaner payer policies you'll see for a relatively new procedure. One covered indication, one primary procedure code, one diagnosis code. That clarity is genuinely helpful for transperineal biodegradable spacer billing.
But "clean" doesn't mean "easy to get paid." The risk here isn't ambiguity — it's documentation gaps. Aetna isn't going to pay CPT 55874 because a patient has C61. They're paying because the patient has C61 and a radiotherapy plan and the spacer placement is documented as protecting against rectal toxicity. All three pieces need to be in the record.
SpaceOAR and Barrigel are both relatively new to widespread clinical use. Some providers are still building their documentation workflows around these products. If your team doesn't have a standard template or order set that captures the radiotherapy intent and rectal protection rationale, build one now — before January 5, 2026.
One more thing: this is a modified policy, not a new one. Something changed between the prior version and the January 5, 2026 version. The billing guidelines and covered criteria described above reflect the current published version. If your practice has been billing CPT 55874 under an older version of CBP 0926, audit those claims against the current criteria. A policy modification can shift what was previously payable.
Get the Full Picture for CPT 55874
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.